

Osteoporosis Drugs Market Analysis By Product (Branded, Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM), Rank Ligand Inhibitors, Generics), And Segment Forecasts, 2014 - 2025

https://marketpublishers.com/r/O6137E20036EN.html

Date: January 2017 Pages: 78 Price: US\$ 5,950.00 (Single User License) ID: O6137E20036EN

Abstracts

The global osteoporosis drugs market is expected to reach USD 16.3 billion by 2025, according to a new study by Grand View Research, Inc. An upsurge rise in the unhealthy lifestyle adoption has resulted in aggravation and increase in the prevalence of osteoporosis which is presumed to propel the osteoporosis drugs market during the forecast period.

In addition, growing number of patent expiries is fueling the high clinical urgency to use generic versions of the established drugs, which is presumed to fuel generic osteoporosis drugs market during the forecast period. The aforementioned factors cumulatively are slated to present the with high potential growth opportunities over the coming years.

Furthermore, rising number of initiatives to increase the awareness levels pertaining to osteoporosis care amongst the patients as well as the physicians is expected to widen the osteoporosis market growth potential during the forecast period. For instance, National Osteoporosis Foundation (NOF), a healthcare organization responsible for National Bone Health Alliance and Fracture Liaison Service (FLS) care coordination programs that focuses on elevating awareness levels as well as provides training to healthcare professionals

Further key findings from the study suggest:



Branded drugs held the dominant share of the product segment in 2015. The dominant share can be attributed to extensive utilization of bisphosphates, rank ligand inhibitors for the treatment of osteoporosis, possessing high efficacy

Generics are expected to witness at a lucrative CAGR owing to consistent patent expiries over the coming years as well as high clinical urgency for inexpensive medication in the emerging economies

In 2015, North America accounted for the largest share in the global osteoporosis drugs market owing to the presence of established companies extensively involved in the commercialization of branded therapeutics

Asia Pacific is anticipated to grow at an exponential CAGR as a consequence of favorable government initiatives promoting information pertaining to osteoporosis care

The key participants are employing sustainability strategies promoting the adoption of osteoporosis therapeutics to gain competitive advantage. For instance, Actavis Inc. announced to acquire Warner Chilcott PLC in order to widen their product portfolio



Contents

CHAPTER 1 RESEARCH METHODOLOGY & SCOPE

- 1.1 Region Wise Market Calculation
- 1.1.1 Region Wise Market: Base Estimates
- 1.1.2 Global Market: CAGR Calculation
- 1.2 Region based segment share calculation
- 1.3 List of Secondary Sources

CHAPTER 2 EXECUTIVE SUMMARY

2.1 Market summary

CHAPTER 3 OSTEOPOROSIS DRUGS MARKET VARIABLES, TRENDS & SCOPE

- 3.1 Market segmentation& scope
 - 3.1.1 Market Driver Analysis
- 3.1.2 Market Restraint Analysis
- 3.2 Penetration & Growth Prospect Mapping
- 3.3 Osteoporosis Drugs SWOT Analysis
- 3.4 Industry Analysis Porter's
- 3.5 Product Pipeline Analysis
- 3.6 Company Market Share, 2015

CHAPTER 4 OSTEOPOROSIS DRUGS PRODUCT ESTIMATES & TREND ANALYSIS

- 4.1 Osteoporosis Drugs Market: Product Movement Analysis
- 4.2 Branded
- 4.2.1 Branded market, 2014 2025 (USD Million)
- 4.2.2 Bisphosphonates
- 4.2.2.1 Bisphosphonates market, 2014 2025 (USD Million)
- 4.2.3 Parathyroid Hormone Therapy
- 4.2.3.1 Parathyroid hormone therapy market, 2014 2025 (USD Million)
- 4.2.4 Calcitonin
- 4.2.4.1 Calcitonin market, 2014 2025 (USD Million)
- 4.2.5 Selective Estrogen Inhibitors Modulator (SERM)
- 4.2.5.1 SERM market, 2014 2025 (USD Million)



4.2.6 Rank Ligand Inhibitors

4.2.6.1 Rank ligand Inhibitors market, 2014 - 2025 (USD Million)

4.2.7 Others

4.2.7.1 Others market, 2014 - 2025 (USD Million)

4.3 Generic

4.3.1 Generic market, 2014 - 2025 (USD Million)

CHAPTER 5 OSTEOPOROSIS DRUGS REGIONAL ESTIMATES & TREND ANALYSIS, BY PRODUCT

5.1 Osteoporosis drugs market share by region, 2015 & 2025

5.2 North America

5.2.1 North America osteoporosis drugs market, 2014 - 2025 (USD Million) 5.2.2 U.S.

5.2.2.1 U.S. osteoporosis drugs market, 2014 - 2025 (USD Million) 5.2.3 Canada

5.2.3.1 Canada osteoporosis drugs market, 2014 - 2025 (USD Million) 5.3 Europe

5.3.1 Europe osteoporosis drugs market, 2014 - 2025 (USD Million) 5.3.2 UK

5.3.2.1 UK osteoporosis drugs market, 2014 - 2025 (USD Million)

5.3.3 Germany

5.3.3.1 Germany osteoporosis drugs market, 2014 - 2025 (USD Million) 5.4 Asia Pacific

5.4.1 Asia Pacific osteoporosis drugs market, 2014 - 2025 (USD Million) 5.4.2 Japan

5.4.2.1 Japan osteoporosis drugs market, 2014 - 2025 (USD Million) 5.4.3 China

5.4.3.1 China osteoporosis drugs market, 2014 - 2025 (USD Million) 5.4.4 India

5.4.4.1 India osteoporosis drugs market, 2014 - 2025 (USD Million)

5.5 Latin America

5.5.1 Latin America osteoporosis drugs market, 2014 - 2025 (USD Million) 5.5.2 Brazil

5.5.2.1 Brazil osteoporosis drugs market, 2014 - 2025 (USD Million)

5.5.3 Mexico

5.5.3.1 Mexico osteoporosis drugs market, 2014 - 2025 (USD Million) 5.6 MEA

5.6.1 MEA osteoporosis drugs market, 2014 - 2025 (USD Million)



5.6.2 South Africa

5.6.2.1 South Africa osteoporosis drugs market, 2014 - 2025 (USD Million)

CHAPTER 6 COMPETITIVE LANDSCAPE

- 6.1 Strategy framework
- 6.2 Market participation categorization
- 6.3 Company Profiles
- 6.3.1 Pfizer, Inc.
 - 6.3.1.1 Company overview
 - 6.3.1.2 Financial performance
 - 6.3.1.3 Geographic Foothold
 - 6.3.1.4 Product benchmarking
 - 6.3.1.5 Strategic initiatives
- 6.3.2 F.Hoffmann La Roche
- 6.3.2.1 Company overview
- 6.3.2.2 Financial performance
- 6.3.2.3 Geographic Foothold
- 6.3.2.4 Product benchmarking

6.3.2.5 Strategic initiatives

- 6.3.3 Teva Pharmaceuticals
 - 6.3.3.1 Company overview
 - 6.3.3.2 Financial performance
 - 6.3.3.3 Geographic Foothold
- 6.3.3.4 Product benchmarking

6.3.4 Novartis AG

- 6.3.4.1 Company overview
- 6.3.4.2 Financial performance
- 6.3.4.3 Geographic Foothold
- 6.3.4.4 Product benchmarking
- 6.3.4.5 Strategic initiatives
- 6.3.5 Merck & Co AG
 - 6.3.5.1 Company overview
- 6.3.5.2 Financial Performance
- 6.3.5.3 Geographic Foothold
- 6.3.5.4 Product benchmarking
- 6.3.5.5 Strategic initiatives
- 6.3.6 Amgen, Inc.
 - 6.3.6.1 Company overview



- 6.3.6.2 Financial performance
- 6.3.6.3 Geographic Foothold
- 6.3.6.4 Product benchmarking
- 6.3.6.5 Strategic initiatives
- 6.3.7 Allergan plc
 - 6.3.7.1 Company overview
 - 6.3.7.2 Financial performance
 - 6.3.7.3 Geographic Foothold
 - 6.3.7.4 Product benchmarking
 - 6.3.7.5 Strategic initiatives
- 6.3.8 GlaxoSmithKline
- 6.3.8.1 Company overview
- 6.3.8.2 Financial performance
- 6.3.8.3 Geographic Foothold
- 6.3.8.4 Product benchmarking
- 6.3.8.5 Strategic initiatives
- 6.3.9 Eli Lilly and Company
- 6.3.9.1 Company overview
- 6.3.9.2 Financial performance
- 6.3.9.3 Geographic Foothold
- 6.3.9.4 Product Benchmarking
- 6.3.9.5 Strategic initiatives



List Of Tables

LIST OF TABLES

 TABLE 1 North America osteoporosis drugs market, by product, 2014 - 2025 (USD
 Million)

TABLE 2 U.S. osteoporosis drugs market, by product, 2014 - 2025 (USD Million) TABLE 3 Canada osteoporosis drugs market, by product, 2014 - 2025 (USD Million) TABLE 4 Europe osteoporosis drugs market, by product, 2014 - 2025 (USD Million) TABLE 5 UK osteoporosis drugs market, by product, 2014 - 2025 (USD Million) TABLE 6 Germany osteoporosis drugs market, by product, 2014 - 2025 (USD Million) TABLE 7 Asia Pacific osteoporosis drugs market, by product, 2014 - 2025 (USD Million) TABLE 8 Japan osteoporosis drugs market, by product, 2014 - 2025 (USD Million) TABLE 9 China osteoporosis drugs market, by product, 2014 - 2025 (USD Million) TABLE 10 India osteoporosis drugs market, by product, 2014 - 2025 (USD Million) TABLE 11 Latin America osteoporosis drugs market, by product, 2014 - 2025 (USD Million)

TABLE 12 Brazil osteoporosis drugs market, by product, 2014 - 2025 (USD Million) TABLE 13 Mexico osteoporosis drugs market, by product, 2014 - 2025 (USD Million) TABLE 14 MEA osteoporosis drugs market, by product, 2014 - 2025 (USD Million) TABLE 15 South Africa osteoporosis drugs market, by product, 2014 - 2025 (USD Million) Million)



List Of Figures

LIST OF FIGURES

- FIG. 1 Market summary
- FIG. 2 Market trends & outlook
- FIG. 3 Market segmentation & scope
- FIG. 4 Market driver relevance analysis (Current & future impact)
- FIG. 5 Market restraint relevance analysis (Current & future impact)
- FIG. 6 Penetration & Growth Prospect Mapping
- FIG. 7 Osteoporosis Drugs SWOT Analysis
- FIG. 8 Porter's Five Forces Analysis
- FIG. 9 Porter's Five Forces Analysis
- FIG. 10 Company Market Share, 2015
- FIG. 11 Osteoporosis drugs market product outlook key takeaways
- FIG. 12 Osteoporosis drugs market: Type movement analysis
- FIG. 13 Branded market, 2014 2025 (USD Million)
- FIG. 14 Bisphosphonates market, 2014 2025 (USD Million)
- FIG. 15 Parathyroid hormone therapy market, 2014 2025 (USD Million)
- FIG. 16 Calcitonin market, 2014 2025 (USD Million)
- FIG. 17 SERM market, 2014 2025 (USD Million)
- FIG. 18 Rank ligand Inhibitors market, 2014 2025 (USD Million)
- FIG. 19 Others market, 2014 2025 (USD Million)
- FIG. 20 Generic market, 2014 2025 (USD Million)
- FIG. 21 Regional market place: Key takeaways
- FIG. 22 Regional outlook, 2015 & 2025
- FIG. 23 North America osteoporosis drugs market, 2014 2025 (USD Million)
- FIG. 24 U.S. osteoporosis drugs market, 2014 2025 (USD Million)
- FIG. 25 Canada osteoporosis drugs market, 2014 2025 (USD Million)
- FIG. 26 Europe osteoporosis drugs market, 2014 2025 (USD Million)
- FIG. 27 UK osteoporosis drugs market, 2014 2025 (USD Million)
- FIG. 28 Germany osteoporosis drugs market, 2014 2025 (USD Million)
- FIG. 29 Asia Pacific osteoporosis drugs market, 2014 2025 (USD Million)
- FIG. 30 Japan osteoporosis drugs market, 2014 2025 (USD Million)
- FIG. 31 China osteoporosis drugs market, 2014 2025 (USD Million)
- FIG. 32 India osteoporosis drugs market, 2014 2025 (USD Million)
- FIG. 33 Latin America osteoporosis drugs market, 2014 2025 (USD Million)
- FIG. 34 Brazil osteoporosis drugs market, 2014 2025 (USD Million)
- FIG. 35 Mexico osteoporosis drugs market, 2014 2025 (USD Million)



- FIG. 36 MEA osteoporosis drugs market, 2014 2025 (USD Million)
- FIG. 37 South Africa osteoporosis drugs market, 2014 2025 (USD Million)
- FIG. 38 Strategy framework
- FIG. 39 Participant categorization



I would like to order

Product name: Osteoporosis Drugs Market Analysis By Product (Branded, Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM), Rank Ligand Inhibitors, Generics), And Segment Forecasts, 2014 - 2025

Product link: https://marketpublishers.com/r/O6137E20036EN.html

Price: US\$ 5,950.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/O6137E20036EN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature ____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below



and fax the completed form to +44 20 7900 3970